Interleukin-17A Antagonists [MoA] - N0000191494
Pharmacologic Class Information
Pharmacologic Code | N0000191494 |
Pharmacologic Name | Interleukin-17A Antagonists |
Pharmacologic Uses |
|
Pharmacologic Concept | Mechanisms of Action - [MoA] |
Pharmacologic Concept Description | This concept refers to the mechanism of action pharmacologic action at the receptor, membrane, or tissue level. In MED-RT, molecular, subcellular, or cellular effects of drug generic ingredients, organized into a chemical function classification hierarchy, beneath the "Cellular or Molecular Interactions" concept. |
NDC Products with Interleukin-17A Antagonists
The table contains 8 products whose active ingredient are classified under the same pharmacologic class Interleukin-17A Antagonists [MoA].
NDC | Proprietary Name | Non-Proprietary Name | Dosage Form | Route Name | Company Name | Status | |
---|---|---|---|---|---|---|---|
0002-7724 | Taltz | Non-Proprietary Name: Ixekizumab | Injection, Solution | Subcutaneous | Eli Lilly And Company | ACTIVE | |
0078-1168 | Cosentyx | Non-Proprietary Name: Secukinumab | Injection, Solution, Concentrate | Intravenous | Novartis Pharmaceuticals Corporation | ACTIVE | |
0078-0639 | Cosentyx | Non-Proprietary Name: Secukinumab | Injection | Subcutaneous | Novartis Pharmaceuticals Corporation | ACTIVE | |
0078-1070 | Cosentyx | Non-Proprietary Name: Secukinumab | Injection | Subcutaneous | Novartis Pharmaceuticals Corporation | ACTIVE | |
0078-1056 | Cosentyx | Non-Proprietary Name: Secukinumab | Injection | Subcutaneous | Novartis Pharmaceuticals Corporation | ACTIVE | |
0002-8900 | Taltz | Non-Proprietary Name: Ixekizumab | Injection, Solution | Subcutaneous | Eli Lilly And Company | ACTIVE | |
0002-8905 | Taltz | Non-Proprietary Name: Ixekizumab | Injection, Solution | Subcutaneous | Eli Lilly And Company | ACTIVE | |
0002-1445 | Taltz | Non-Proprietary Name: Ixekizumab | Injection, Solution | Subcutaneous | Eli Lilly And Company | ACTIVE |